Remdesivir increases mtDNA copy number causing mild alterations to oxidative phosphorylation

SARS-CoV-2 causes the severe respiratory disease COVID-19. Remdesivir (RDV) was the first fast-tracked FDA approved treatment drug for COVID-19. RDV acts as an antiviral ribonucleoside (adenosine) analogue that becomes active once it accumulates intracellularly. It then diffuses into the host cell a...

Descripción completa

Detalles Bibliográficos
Autores principales: DeFoor, Nicole, Paul, Swagatika, Li, Shuang, Basso, Erwin K. Gudenschwager, Stevenson, Valentina, Browning, Jack L., Prater, Anna K., Brindley, Samantha, Tao, Ge, Pickrell, Alicia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504289/
https://www.ncbi.nlm.nih.gov/pubmed/37714940
http://dx.doi.org/10.1038/s41598-023-42704-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504289/
https://www.ncbi.nlm.nih.gov/pubmed/37714940
http://dx.doi.org/10.1038/s41598-023-42704-y

Ejemplares similares